Cargando…
Creating an arsenal of Adeno-associated virus (AAV) gene delivery stealth vehicles
The Adeno-associated virus (AAV) gene delivery system is ushering in a new and exciting era in the United States; following the first approved gene therapy (Glybera) in Europe, the FDA has approved a second therapy, Luxturna [1]. However, challenges to this system remain. In viral gene therapy, the...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933702/ https://www.ncbi.nlm.nih.gov/pubmed/29723270 http://dx.doi.org/10.1371/journal.ppat.1006929 |